Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025

Biocon inaugurates first US manufacturing facility in New Jersey

Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing

Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients

Lonza appoints Jason Berndt as Head of Group Operations

Maria Soler Nunez appointed as Chief Quality Officer

Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery

Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile

FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development